Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide-formoterol in chronic cough suggestive of cough variant asthma
NCT06590740Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of budesonide + formoterol in cough variant asthma (CVA), sponsored by AstraZeneca. Started Oct 2024; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
cough variant asthma (CVA)
Beyond the preview
Go deeper on NCT06590740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590740.